scFv(PSMA)-CD28-CD3zeta CAR-T Lentivirus

The scFv(PSMA)-CD28-CD3zeta CAR-T Lentivirus is a specialized gene transfer tool designed to engineer T cells for the targeted destruction of PSMA-positive malignant cells. The vector encodes a second-generation chimeric antigen receptor (CAR) that utilizes a high-affinity single-chain variable fragment (scFv) to identify Prostate-Specific Membrane Antigen (PSMA), a protein significantly overexpressed in prostate cancer tissues. This recognition unit is fused to a CD28 costimulatory signaling domain and a CD3-zeta activation domain. The use of a lentiviral backbone ensures stable, long-term expression of the CAR transgene through genomic integration, allowing for the generation of a consistent population of therapeutic T cells. This specific configuration is optimized to trigger robust T-cell activation and proliferation upon antigen binding, leveraging the CD28 domain to enhance the survival and metabolic fitness of the cells within the often hostile tumor microenvironment.

This lentiviral product serves as a critical component in the research and development of cell-based immunotherapies for solid tumors. It is primarily used to transduce primary T cells or T-cell lines to create effector cells for functional characterization, such as antigen-specific lysis assays and cytokine release profiling (IFN-gamma and IL-2). Beyond in vitro studies, it is an essential tool for evaluating therapeutic efficacy in vivo using prostate cancer xenograft mouse models, where researchers monitor tumor growth inhibition and CAR-T cell persistence over time. Furthermore, the vector is frequently employed in studies investigating the impact of different hinge regions or the synergy between CAR-T cells and other therapeutic modalities, such as checkpoint inhibitors or targeted small molecules. By providing high transduction efficiency and reliable CAR expression, this lentivirus enables the systematic optimization of treatment strategies aimed at overcoming the challenges of prostate cancer immunotherapy.